Pushing the boundaries
of innovation in oncology.
Pushing the boundaries of
innovation in oncology.
Company Values
At Cullinan Oncology, our pursuit to positively impact the lives of patients with cancer and their families is central to who we are and what we do. Our values reflect our intrinsic commitment to scientific innovation and our purposeful action with urgency. Our unique culture fuels our passion to create new standards of care for patients with cancer.
Leadership
Advisors
Board of Directors
Jeff is as an accomplished financial professional with biotechnology experience from operational as well as investment banking and capital markets roles. Prior to joining Cullinan Oncology, Jeff most recently served as CFO at Amylyx Pharmaceuticals where he established the company’s Finance and Accounting operations and oversaw the successful completion of a Series B financing. Jeff joined Amylyx after serving as a Vice President at BlueRock Therapeutics, an engineered cell and gene therapy company, where he played a leading role in building out the finance function and supporting its sale to Bayer AG in a transaction that valued BlueRock up to $1 billion. Previously, Jeff held corporate finance and strategy roles at Alexion Pharmaceuticals, a global biotechnology company focused on rare diseases, and in Healthcare Investment Banking and Equity Capital Markets at RBC Capital Markets and Credit Suisse. 
Dr. Wigginton most recently served as the Chief Medical Officer at MacroGenics (NASDAQ:MGNX), where he led the company’s evolution of a fully-integrated, clinical-stage cancer immunotherapy organization. This included the translation of ten new molecules into the clinic, including early phase and/or proof-of-concept studies with bispecific molecules, checkpoint inhibitors, Fc-optimized antibodies and antibody drug conjugates, as well as the design and execution of registration-directed studies.
Ray has served as our Chief Legal Officer since December 2020. Before joining the Company, Ray served as Chief Legal Officer, Chief Compliance Officer and Corporate Secretary of Intarcia Therapeutics, Inc. from September 2013 through April 2020. Prior to this, he served at Ariad Pharmaceuticals Inc., or Ariad, from 2008 through 2013 as Senior Vice President, General Counsel, Secretary and Chief Compliance Officer. Prior to his tenure at Ariad, Ray served in increasing roles of responsibility at Bristol-Myers Squibb from 1988 until 2008, most recently as Chief Counsel, Global Marketing and Strategic Development. Ray has also served on various private company boards of directors. Ray holds a B.A. from Fordham University and a J.D. from Fordham University School of Law.
